These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27075367)

  • 1. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
    Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
    J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
    Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
    J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
    Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
    Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
    J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
    Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
    J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
    Reynoird N; Mazur PK; Stellfeld T; Flores NM; Lofgren SM; Carlson SM; Brambilla E; Hainaut P; Kaznowska EB; Arrowsmith CH; Khatri P; Stresemann C; Gozani O; Sage J
    Genes Dev; 2016 Apr; 30(7):772-85. PubMed ID: 26988419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
    Yi X; Jiang XJ; Fang ZM
    Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of substrate methylation and inhibition of SMYD2.
    Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
    Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
    Brown MA; Sims RJ; Gottlieb PD; Tucker PW
    Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
    Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
    Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
    Weirich S; Schuhmacher MK; Kudithipudi S; Lungu C; Ferguson AD; Jeltsch A
    Chembiochem; 2020 Jan; 21(1-2):256-264. PubMed ID: 31612581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
    Fan JD; Lei PJ; Zheng JY; Wang X; Li S; Liu H; He YL; Wang ZN; Wei G; Zhang X; Li LY; Wu M
    PLoS One; 2015; 10(1):e0116782. PubMed ID: 25562686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.
    Butler KV; Ma A; Yu W; Li F; Tempel W; Babault N; Pittella-Silva F; Shao J; Wang J; Luo M; Vedadi M; Brown PJ; Arrowsmith CH; Jin J
    J Med Chem; 2016 Nov; 59(21):9881-9889. PubMed ID: 27804297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
    Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
    Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.
    Chandramouli B; Melino G; Chillemi G
    Mol Oncol; 2019 Jun; 13(6):1450-1461. PubMed ID: 31069954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
    Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
    J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.